A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
Crossref DOI link: https://doi.org/10.1007/s15010-016-0894-y
Published Online: 2016-04-09
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Watt, Maureen
McCrea, Charles
Johal, Sukhvinder
Posnett, John
Nazir, Jameel
Funding for this research was provided by:
Astellas Pharma Europe
License valid from 2016-04-09